One Man Quit the FDA. Gene Therapy Stocks Went Berserk.

Then came the workplace complaints. By late February 2026, Prasad was under investigation by the FDA for fostering a toxic work environment. The allegations included "retaliation against subordinates and verbally berating staff." George Tidmarsh, who briefly led the FDA's drug review center before leaving in November 2025, pointed to Prasad as the source of the toxicity.

And the regulatory whiplash kept coming. In February 2026, CBER issued a refuse-to-file letter to Moderna for its flu vaccine, mRNA-1010. A week later, that decision was reversed. For an industry that stakes billions on regulatory predictability, this was like playing poker with someone who keeps changing the rules mid-hand.

Why Wall Street Threw a Party

So when news broke that Prasad would leave at the end of April 2026, returning to his academic post at UCSF, the market reaction was swift and dramatic.

uniQure surged roughly 26% on March 9. The rally continued into the next day's pre-market trading, with shares climbing another 7%. And it wasn't just uniQure; a broader wave of genetic medicine stocks caught a bid as traders bet that the regulatory ice age for gene therapies might be thawing.

Analysts scrambled to upgrade their calls. RBC Capital bumped uniQure to Outperform and tripled its price target from $11 to $35, assigning 50% odds that AMT-130 could still win approval. H.C. Wainwright reiterated a Buy rating with a $70 target, citing a "reshaped regulatory outlook." Chardan raised its target to $31. Stifel called the departure a win for all rare disease biotechs, noting Prasad's history of overruling his own review teams.

Retail investors piled in too. On platforms like Stocktwits, the phrase "gene therapy trade reset" was everywhere.

The Hangover Was Quick

But reality has a way of catching up. Trading volume dropped sharply, a sign that the initial euphoria was fading and sellers were stepping in.

The underlying challenges haven't disappeared just because one person left. uniQure's stock was still trading at approximately $17.99 on its rally day, compared to a 52-week high of $71.50. The company carries negative operating margins (a staggering -1,236%) and a return on equity of -174%. Goldman Sachs, playing the skeptic, has a $9 price target on the stock. And the FDA recently rebuked uniQure for allegedly "distorted" data, a cloud that doesn't vanish with a personnel change. Class-action lawsuits are in play too.

The fundamental question remains: will a new CBER director accept the existing Phase I/II data for AMT-130, or will Prasad's demand for a Phase 3 trial stick? No successor has been named yet, though Makary says one will be announced before Prasad's exit.

The Bigger Picture Is Fascinating

What makes this story remarkable isn't really about uniQure or Prasad. It's about how a single regulatory appointment can redirect billions of dollars in market value across an entire therapeutic sector.

Consider the contrast with Prasad's predecessor. Under Peter Marks, CBER reorganized in 2023 to create a dedicated Office of Therapeutic Products, which led to 10 new rare disease therapy approvals, roughly double the prior pace. That era felt like spring for gene therapy companies. Prasad's arrival felt like winter.

The gene therapy pipeline is still massive: roughly 264 agents are in development, with several key FDA decisions coming in 2026. Ultragenyx has a decision date in August for its gene therapy for glycogen storage disease. Neurogene is running a registrational trial for Rett syndrome. The FDA's new "plausible mechanism" framework, ironically co-authored by Prasad himself, could open doors for custom CRISPR therapies targeting ultra-rare diseases.

But all of that potential sits on a razor's edge, balanced by whoever walks into CBER's corner office next.

What to Watch

The successor announcement is the next catalyst. If Makary picks someone with Marks-style flexibility, expect another rally across genetic medicine stocks. If the next director continues Prasad's approach (demanding larger trials, questioning prior agreements), the sector's discount will deepen.

For now, the gene therapy trade is essentially a bet on a hiring decision. That might sound absurd for a sector built on cutting-edge science. But in biotech, the person reviewing your homework matters just as much as the homework itself.

Immutep Lost Most of Its Value in a Single Day. Here's Why.

Immutep's stock cratered roughly 90% after an independent committee pulled the plug on its most important lung cancer trial. The failure raises tough questions about a once-promising immunotherapy approach and adds to a brutal streak of late-stage clinical disasters.